Literature DB >> 21688276

Heart failure after myocardial infarction: clinical implications and treatment.

Marcos F Minicucci1, Paula S Azevedo, Bertha F Polegato, Sergio A R Paiva, Leonardo A M Zornoff.   

Abstract

Heart failure is a frequent complication of myocardial infarction. Several factors, such as recurrent myocardial ischemia, infarct size, ventricular remodeling, stunned myocardium, mechanical complications, and hibernating myocardium influence the appearance of left ventricular systolic dysfunction after myocardial infarction. Importantly, its presence increases the risk of death by at least 3- to 4-fold. The knowledge of the mechanisms and clinical features are essential for the diagnosis and treatment of left ventricular dysfunction and heart failure after myocardial infarction. Therefore, this review will focus on the clinical implications and treatment of heart failure after myocardial infarction.
© 2011 Wiley Periodicals, Inc. The authors have no funding, financial relationships, or conflicts of interest to disclose. © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21688276      PMCID： PMC6652587          DOI： 10.1002/clc.20922

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN： 0160-9289            Impact factor:   2.882


  36 in total

1.  Treatment of acute heart failure: out with the old, in with the new.

Authors:  Philip A Poole-Wilson
Journal:  JAMA       Date:  2002-03-27       Impact factor: 56.272

2.  Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.

Authors:  H J Dargie
Journal:  Lancet       Date:  2001-05-05       Impact factor: 79.321

3.  Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation.

Authors:  C Torp-Pedersen; L Køber
Journal:  Lancet       Date:  1999-07-03       Impact factor: 79.321

4.  Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

Authors:  Bertram Pitt; Willem Remme; Faiez Zannad; James Neaton; Felipe Martinez; Barbara Roniker; Richard Bittman; Steve Hurley; Jay Kleiman; Marjorie Gatlin
Journal:  N Engl J Med       Date:  2003-03-31       Impact factor: 91.245

5.  Meta-analysis of corticosteroid treatment in acute myocardial infarction.

Authors:  Gregory R Giugliano; Robert P Giugliano; C Michael Gibson; Richard E Kuntz
Journal:  Am J Cardiol       Date:  2003-05-01       Impact factor: 2.778

6.  Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan.

Authors:  Kenneth Dickstein; John Kjekshus
Journal:  Lancet       Date:  2002-09-07       Impact factor: 79.321

7.  Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction.

Authors:  Masaru Hayashi; Takayoshi Tsutamoto; Atsuyuki Wada; Takashi Tsutsui; Chitose Ishii; Keijin Ohno; Masanori Fujii; Atsushi Taniguchi; Tomokazu Hamatani; Yoshitaka Nozato; Ken Kataoka; Naoki Morigami; Masato Ohnishi; Masahiko Kinoshita; Minoru Horie
Journal:  Circulation       Date:  2003-05-05       Impact factor: 29.690

8.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.

Authors:  M A Pfeffer; E Braunwald; L A Moyé; L Basta; E J Brown; T E Cuddy; B R Davis; E M Geltman; S Goldman; G C Flaker
Journal:  N Engl J Med       Date:  1992-09-03       Impact factor: 91.245

9.  Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology.

Authors:  Frans Van de Werf; Diego Ardissino; Amadeo Betriu; Dennis V Cokkinos; Erling Falk; Keith A A Fox; Desmond Julian; Maria Lengyel; Franz-Josef Neumann; Witold Ruzyllo; Christian Thygesen; S Richard Underwood; Alec Vahanian; Freek W A Verheugt; William Wijns
Journal:  Eur Heart J       Date:  2003-01       Impact factor: 29.983

10.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

Authors:  Marc A Pfeffer; John J V McMurray; Eric J Velazquez; Jean-Lucien Rouleau; Lars Køber; Aldo P Maggioni; Scott D Solomon; Karl Swedberg; Frans Van de Werf; Harvey White; Jeffrey D Leimberger; Marc Henis; Susan Edwards; Steven Zelenkofske; Mary Ann Sellers; Robert M Califf
Journal:  N Engl J Med       Date:  2003-11-10       Impact factor: 91.245
View more
  58 in total

Review 1.  Injectable Hydrogels for Cardiac Tissue Engineering.

Authors:  Brisa Peña; Melissa Laughter; Susan Jett; Teisha J Rowland; Matthew R G Taylor; Luisa Mestroni; Daewon Park
Journal:  Macromol Biosci       Date:  2018-05-07       Impact factor: 4.979

2.  Anisotropic microfibrous scaffolds enhance the organization and function of cardiomyocytes derived from induced pluripotent stem cells.

Authors:  Maureen Wanjare; Luqia Hou; Karina H Nakayama; Joseph J Kim; Nicholas P Mezak; Oscar J Abilez; Evangeline Tzatzalos; Joseph C Wu; Ngan F Huang
Journal:  Biomater Sci       Date:  2017-07-25       Impact factor: 6.843

3.  Silent Myocardial Infarction and Long-Term Risk of Heart Failure: The ARIC Study.

Authors:  Waqas T Qureshi; Zhu-Ming Zhang; Patricia P Chang; Wayne D Rosamond; Dalane W Kitzman; Lynne E Wagenknecht; Elsayed Z Soliman
Journal:  J Am Coll Cardiol       Date:  2018-01-02       Impact factor: 24.094

4.  VEGF-C/VEGFR-3 pathway promotes myocyte hypertrophy and survival in the infarcted myocardium.

Authors:  Tieqiang Zhao; Wenyuan Zhao; Weixin Meng; Chang Liu; Yuanjian Chen; Ivan C Gerling; Karl T Weber; Syamal K Bhattacharya; Rahul Kumar; Yao Sun
Journal:  Am J Transl Res       Date:  2015-04-15       Impact factor: 4.060

Review 5.  Cardiac Fibroblast Activation Post-Myocardial Infarction: Current Knowledge Gaps.

Authors:  Yonggang Ma; Rugmani Padmanabhan Iyer; Mira Jung; Michael P Czubryt; Merry L Lindsey
Journal:  Trends Pharmacol Sci       Date:  2017-03-29       Impact factor: 14.819

6.  Systolic Dysfunction in Infarcted Mice Does Not Necessarily Lead to Heart Failure: Need to Refine Preclinical Models.

Authors:  María Villalba-Orero; Marina López-Olañeta; Pablo García-Pavía; Enrique Lara-Pezzi
Journal:  J Cardiovasc Transl Res       Date:  2017-08-15       Impact factor: 4.132

7.  Cardiac responses to hypoxia and reoxygenation in Drosophila.

Authors:  Rachel Zarndt; Sarah Piloto; Frank L Powell; Gabriel G Haddad; Rolf Bodmer; Karen Ocorr
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-09-16       Impact factor: 3.619

8.  Mortality Associated With Heart Failure After Myocardial Infarction: A Contemporary Community Perspective.

Authors:  Yariv Gerber; Susan A Weston; Maurice Enriquez-Sarano; Cecilia Berardi; Alanna M Chamberlain; Sheila M Manemann; Ruoxiang Jiang; Shannon M Dunlay; Véronique L Roger
Journal:  Circ Heart Fail       Date:  2015-12-23       Impact factor: 8.790

Review 9.  The role of ubiquitin ligases in cardiac disease.

Authors:  Monte S Willis; Ariana Bevilacqua; Thomas Pulinilkunnil; Petra Kienesberger; Manasi Tannu; Cam Patterson
Journal:  J Mol Cell Cardiol       Date:  2013-11-19       Impact factor: 5.000

10.  Evaluation of Hydrogels Presenting Extracellular Matrix-Derived Adhesion Peptides and Encapsulating Cardiac Progenitor Cells for Cardiac Repair.

Authors:  Srishti Bhutani; Aline L Y Nachlas; Milton E Brown; Tionne Pete; Christopher T Johnson; Andres J García; Michael E Davis
Journal:  ACS Biomater Sci Eng       Date:  2017-11-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.